低分子肝素联合安步乐克治疗重度下肢缺血的前瞻性研究

The prospective study of low molecule weight heparin cooperated with sarpogrelate for serious lower extremity ischemia

目的:前瞻性随机对照研究,低分子肝素联合安步乐克治疗重度下肢缺血。方法:将83例重度下肢缺血患者随机分为治疗组及对照组,分别给予低分子肝素、安步乐克、培达和胰激肽释放酶,并比较两组间的疗效性及安全性。结果:治疗组显效率38.5%(30/78),有效率48.7%(38/78),无效率12.8%(10/78);对照组显效率10.1%(7/69),有效率14.5%(10/69),无效率为75.4%(52/69)(P<0.001);两组皆无出血病例。结论:低分子肝素与安步乐克联合应用,可以起到协同作用,不仅可以增加下肢缺血FontaineⅡ期患者的跛行距离,更能使下肢缺血FontaineⅢ及Ⅳ期患者的静息痛减轻或消失,促进侧枝动脉形成,同时也未增加出血风险,体现了两者联合的有效性及安全性。

Objective：The arm of trial is to study to treat serious lower extremity ischemia by low molecule weight heparin（LMWH）cooperated with sarpogrelate.Methods： We conducted a randomized cohort trial,in which 43 patients（experimental group） were assigned to apply LMWH cooperated with sarpogrelate,40 patients（compared group） were assigned to apply cilostazol cooperated with pancreatic kallikrein.To compare their validity and security between 2 groups.Results： The excellent,productive and invalid ratio of the experimental group are respectively 38.5%（30/78）,48.7%（38/78）and 12.8%（10/78）.Them of the compared group are respectively 10.1%（7/69）,14.5%（10/69）and 75.4%（52/69）（P0.001）.There is none of bleeding in two groups.Conclusion： LMWH cooperated with sarpogrelate plays a big role in increasing distance of claudication in FontaineⅡ,eliminating or alleviating rest pain in Fontaine Ⅲ or Ⅳ,promoting to form lateral branch artery,and no in increasing blooding.These give expression to validity and security in treatment of LMWH cooperated with sarpogrelate.